Ipsen posts strong growth in 2018 sales and profit

Shares of French pharma company Ipsen (Euronext: IPN) were up 5.6% at 115.70 euros by 11.18 CET this morning, after the company presented financial results for full-year 2018, showing that group sales grew 16.6% as reported and 20.1% at constant exchange rates to reach 2.22 billion euros ($2.51 billion).

Specialty Care sales grew 24.7% to 1.92 billion euros,  reflecting strong performance across all major products and geographies, and Consumer Healthcare  revenues grew 2.7% to 300 million euros. Core operating income came in at 659.9 million euros, with growth of 31.0%. Core earnings per share were 5.91 euros, up 35.5%. Core operating margin at 29.7% of net sales was up 3.3 points.

2019 financial guidance